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In this issue of the journal, Verna et al1 report on an
association between the extent of epicardial endothelial
dysfunction in response to acetylcholine stimulation and
the degree of exercise-induced regional myocardial per-
fusion defect as determined by single photon emission
tomography (SPECT) and technetium 99m tetrofosmin
in patients without ﬂow-limiting epicardial lesions. In-
vestigations by Zeiher et al2 were ﬁrst to demonstrate
that endothelial dysfunction of the coronary microcircu-
lation may be paralleled by exercise-induced regional
myocardial perfusion defects in patients without ﬂow-
limiting artery lesions. The current investigation is in
accord with these earlier observations2 but extends them
now to a moderate association between epicardial endo-
thelial dysfunction in response to intracoronary acetyl-
choline stimulation and the degree of exercise-induced
perfusion defect. Such ﬁndings may indeed suggest that,
even in the absence of focal coronary artery lesions of
greater than 50% diameter stenosis, functional abnormal-
ities of the epicardial conductance vessels may also
affect myocardial perfusion during bicycle stress exer-
cise. Thus current and previous observations3-6 indi-
cate that coronary ﬂow increases during bicycle stress
exercise or during pharmacologic vasodilation are
likely to reﬂect ﬂow-mediated alterations of the epi-
cardial conduit arteries and the coronary arteriolar
resistance vessels together, rather than being represen-
tative of vasomotor function of the arteriolar vessels
alone.4,7-12 Notably, the authors “normalized” the
degree of exercise-induced perfusion defect to the
corresponding extent of perfusion defect during phar-
macologically induced vascular smooth muscle cell
relaxation. This was performed by calculating the
difference between the extent of the perfusion defects
during exercise and pharmacologic vasodilation. The
difference in stress-induced perfusion defects or, as
the authors suggest, a so-called perfusion mismatch
during different forms of vasomotor stress signiﬁ-
cantly correlated with the extent of epicardial endo-
thelial dysfunction (r  0.50, P  .04).1 The latter
association may emphasize that abnormalities in epi-
cardial vasomotor function may indeed account for or
contribute to exercise-induced perfusion defect in
patients without ﬂow-limiting coronary artery lesions.
These new ﬁndings of Verna et al1 may add to the
previous observations of Gould et al,3,5 which described
a relationship between diffuse epicardial coronary artery
disease (CAD) and longitudinal scintigraphic perfusion
defects during dipyridamole stimulation. With positron
emission tomography (PET) measurements of myocar-
dial blood ﬂow in milliliters per gram per minute during
pharmacologic vasodilation or sympathetic stimulation
to cold pressor testing (or both), a relative longitudinal
decrease in myocardial blood ﬂow from the base to the
apical portion of the left ventricle was also observed in
patients with risk factors for CAD.13,14 The mechanism
underlying this stress-induced longitudinal perfusion
gradient or heterogeneity in left ventricular myocardial
perfusion is most likely related to downstream ﬂuid
dynamic consequences of functional or structural alter-
ations of the coronary circulation.15-20 According to the
Hagen-Poiseuille equation,15-17 intracoronary resistance
is determined by the length of the coronary vessel
segment and the ﬂow velocity, but it also depends
inversely on the fourth power of the vessel diameter.
Therefore even minor functional or structural alterations
of the coronary circulation may interfere with a ﬂow-
mediated adjustment of the vessel diameter to higher
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ﬂow velocities.15 The latter interference15,20 may lead to
a progressive decline in intracoronary pressure and,
hence, to a progressive decrease in myocardial perfusion
in the base to the apex direction of the left ventri-
cle.3,5,6,13,14,21
As previous invasive investigations have shown,9,18
increases in coronary ﬂows due to pharmacologic vaso-
dilation of the coronary arteriolar resistance vessels are
normally associated with a ﬂow-mediated and, thus,
endothelium-dependent vasodilation predominantly at
the site of the epicardial artery. In the presence of
endothelial dysfunction, however, pharmacologically in-
duced increases in coronary ﬂows do not translate into a
ﬂow-mediated increase in epicardial diameter, and there-
fore the vessel diameter remains virtually unchanged.9,22
The abnormal vasomotor response to exercise stress,
however, may actually differ from the response during
pharmacologic vasodilation in that it may also cause a
sympathetically mediated coronary vasoconstriction.23-26
It follows then that, in the absence of ﬂow-limiting
epicardial lesions, myocardial perfusion defects during
exercise stress are possibly related to an impairment of
ﬂow-mediated vasodilation resulting from coronary en-
dothelial dysfunction and, at the same time, to a decrease
in coronary artery diameter as a result of a sympatheti-
cally mediated contraction of the vascular smooth mus-
cle cells. In contrast, myocardial perfusion defects
during pharmacologically induced ﬂow increases are
more likely to be related predominantly to CAD-induced
structural alterations of the arterial wall, apart from the
presence of a functional endothelial abnormality, and
thus reﬂecting a relative anatomic stenosis.3,5 Such
consideration may provide some rationale for the current
observations of Verna et al1 that the extent of the
myocardial perfusion defect was greater during exercise
than during pharmacologic vasodilation. A sympatheti-
cally mediated vasoconstriction of a coronary stenosis
during exercise, as Hess et al23 have shown, may
account for more severe and larger perfusion defects
during exercise than during pharmacologic vasodila-
tion. This functional component, which has an addi-
tive effect on the structural stenosis, would then
correlate to the endothelium-related functional distur-
bance as elicited with acetylcholine in the current study.1
The latter angiographic observations of Hess et al23 may
also explain the observed larger perfusion defects during
exercise than during dipyridamole stimulation as deter-
mined recently by nitrogen-13 ammonia PET,27 which
deserves further investigation.
Similarly, SPECT-determined myocardial perfusion
during exercise manifested in greater, more severe and
reversible perfusion defects than during dipyridamole
stimulation.28-31 Comparative investigations with exer-
cise and adenosine stimulation, however, did not always
demonstrate a difference in defect size.28,31 For example,
in a study conducted by David et al,29 only 45% of
patients had larger SPECT-determined regional perfu-
sion defects during exercise than with dipyridamole.
Conceptually, if increases in heart rate and in blood
pressures as a result of sympathetic stress, as previous
investigations have shown,32 are related to increases in
serum norepinephrine concentrations as an index of
sympathetic stimulation, then an association between an
increase in heart rate and exercise-induced myocardial
perfusion defects should be observed, which would
indeed indicate that the degree of exercise-induced per-
fusion defects is related to the extent of the sympathet-
ically mediated coronary vasoconstriction during exer-
cise.23 Indeed, David et al29 observed that larger exercise
defects were realized in those patients with heart rate
increases of greater than 60 beats/min during exercise
from rest than in those with exercise-induced lower heart
rate increases (60 beats/min). It is noteworthy that, in
the study of Chow et al,27 larger and more severe
perfusion defects during exercise than during dipyridam-
ole stimulation were more obvious in patients with mild
to moderate perfusion defects during dipyridamole. The
reason for this observation remains uncertain but is
possibly related to less advanced CAD-induced vessel
stiffness in these patients as possibly reﬂected by mild to
moderate perfusion defects during dipyridamole, where
the exercise-induced coronary vasoconstriction may still
predominate and cause a larger and more severe perfu-
sion defect. In this regard, a predominance of the
functional vasoconstrictor component may dominate, for
example, in mild CAD or, as shown in studies by Zeiher
and colleagues, as well as by other authors,7,9,19,20,22,33-36
in minor, nonsigniﬁcant CAD lesions, and it might give
rise to “false-positive” scintigraphic perfusion imaging
ﬁndings only when compared with coronary angio-
graphic ﬁndings.5,6,21 For the same reason, as several
studies have suggested,34,37-42 endothelial dysfunction or
exercise stress–induced perfusion defects (or both) con-
tain more predictive information on CAD progression
and future cardiovascular events than ﬁndings on coro-
nary angiography alone. On the other hand, as proposed
by Gould et al,5,21 a PET-determined longitudinal perfu-
sion gradient or defect during pharmacologic vasodila-
tion may identify early diffuse CAD. Thus, myocardial
perfusion defects during pharmacologic vasodilation are
likely to be more closely associated with the structural
change in the coronary vessels as noted on coronary
angiography.3,5 This may also accord with the ﬁndings of
Nishimura et al,43 who observed larger perfusion defects
during adenosine stimulation than during exercise
thallium 201 SPECT. Conceptually, it is possible that
in the latter population studied,43 patients had more
advanced focal coronary artery lesions (70%-80%
770 Schindler and Schelbert Journal of Nuclear Cardiology
“Mismatch” in regional myocardial perfusion defects November/December 2007
diameter stenosis) or diffuse CAD (or both), where an
exercise-related and sympathetically induced vascular
smooth muscle cell contraction may not effectively
translate into an additional coronary vasoconstriction
and, thus, may not cause larger and more severe
perfusion defects during exercise than during adeno-
sine stimulation. The emerging new concept, however,
in which scintigraphic perfusion imaging may delineate
the continuous range from early CAD-induced functional
or structural alterations of the coronary circulation to
severe focal stenosis, might also explain the less-than-
optimal speciﬁcity as reported in several studies that
compared scintigraphic myocardial perfusion imaging
with coronary angiography, when a signiﬁcant coronary
artery lesion was deﬁned as 50% diameter narrowing or
greater.44-48
Taken together, although perfusion defects during
dipyridamole stimulation may predominantly reﬂect the
structural stenosis,5 the exercise study most likely dem-
onstrates the effects of both coronary structural and
functional abnormalities on myocardial perfusion.1 This
contention might explain the ﬁndings of Verna et al1 and
the proposed concept of a so-called mismatch in myo-
cardial perfusion defects during different forms of vaso-
motor stress. In this setting, a greater perfusion defect
during exercise stress than during dipyridamole stimula-
tion (positive ratio of exercise to dipyridamole-induced
perfusion defects) may identify predominantly early
functional abnormalities of the coronary circulation,
whereas the inverse (negative) ratio could in fact denote
more CAD-induced structural changes of the arterial
wall.31,49 Although this consideration may be intuitively
correct, it needs direct conﬁrmation of “cause and effect”
through prospective clinical investigations. As the au-
thors mention, however, it remains unclear how their
approach to assess myocardial perfusion combined with
different forms of vasomotor stress may distinguish
between exercise-induced perfusion defects resulting
from ﬂow-limiting epicardial stenosis and those without
them.1 Other variables such as stress-induced typical
angina pectoris and signiﬁcant ST-segment depression,
which are frequently associated with stress-induced
myocardial perfusion defects underlying a ﬂow-limiting
epicardial stenosis, could provide further important di-
agnostic information.50 Although the mean sensitivity
and speciﬁcity of exercise stress–induced ST-segment
depression in the detection of ﬂow-limiting epicardial
stenosis of 63% and 74%, respectively, in several stud-
ies51-54 are rather low, such information could possibly
add useful information to SPECT perfusion imaging to
differentiate between early stages of CAD-induced func-
tional or structural abnormalities and an advanced
focal ﬂow-limiting epicardial stenosis. Another possi-
bility is to apply multidetector-row computed tomog-
raphy (MDCT) in the noninvasive evaluation of coronary
morphology, which could add more deﬁnite informa-
tion,55-60 at the expense of a further increase in non-
negligible ionizing radiation exposure.61 Applying elec-
trocardiography-triggered tube modulation, however,
can lower the radiation dose to 4.3 mSv,62 and further
efforts are being made to reduce the radiation expo-
sure of MDCT without compromising the diagnostic
accuracy.63 Future cardiac imaging protocols could im-
plement MDCT–coronary angiography to identify the
morphology and structure of the arterial wall in early as
well as more advanced stages of the CAD process and its
downstream effects on scintigraphically measured myo-
cardial perfusion. With this approach, the combined
application of SPECT-MDCT or hybrid SPECT-MDCT
scanners45,58,64-67 could expand the diagnostic scope of
conventional SPECT perfusion imaging not only to
identify ﬂow-limiting epicardial lesions but also to detect
and characterize early CAD-related alterations in coro-
nary function and morphology. Because early alterations
in function or morphology of the coronary arterial wall
may provide important predictive information for future
cardiovascular events, in addition to that derived from
traditional coronary risk factor assessment,45,68,69 an
improvement in altered coronary function or morphol-
ogy in developing CAD as a result of preventive
medical intervention has awakened a general inter-
est.70,71 Whether medical interventions tailored to
normalize early abnormalities in coronary function
and morphology also mitigate an improved clinical
outcome in individuals with subclinical or clinically
manifest CAD remains to be established. The assess-
ment of alterations in coronary function and morphol-
ogy by SPECT/PET and MDCT, however, could be
promising to successfully guide preventive medical
intervention in CAD patients.
The investigation by Verna et al1 adds to a new
evolving concept that scintigraphic myocardial perfu-
sion with SPECT or PET may identify and character-
ize the continuous CAD process from early alterations
in coronary function and morphology to anatomic
ﬂow-limiting epicardial stenosis.3,5,6,13,14 Their inves-
tigation suggests that myocardial perfusion imaging
by means of SPECT combined with different forms of
vasomotor stress, such as bicycle exercise and phar-
macologic vasodilation, may be a unique tool by
which to identify early changes in coronary function
and morphology, providing important diagnostic and
prognostic information.3,6,40,45,72 The validity and
value of the latter approach to assess noninvasively
CAD-related early functional and structural abnormal-
ities of the arterial wall, however, need to be estab-
lished in further clinical investigations.
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